It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and others) with the aim of generating cheaper medicines. How, you ask, are they going to do that? Are they aiming for cheaper generics? The state of California has been talking about that, but it's a tough place to work in. The high-volume generic drugs are already competing